Last reviewed · How we verify
RDEA3170 2.5
At a glance
| Generic name | RDEA3170 2.5 |
|---|---|
| Sponsor | Ardea Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RDEA3170 Tablet and Capsule Bioavailability Study (PHASE1)
- Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects (PHASE2)
- RDEA3170 Bioavailability Study (PHASE1)
- RDEA3170 and Febuxostat Combination Study in Gout Subjects (PHASE2)
- A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients (PHASE1, PHASE2)
- Single and Multiple Dose Study in Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |